Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
The Terminate AF Trial and the ICE-AFIB Trial
20 views
August 11, 2023
Randolph Martin, MD speaks with Eric Lehr, MD, and Niv Ad, MD about the treatment ...
read more ↘ of atrial fibrillation and the two trials the doctors are currently leading.
Dr. Lehr discusses the Medtronic Terminate AF Trial with the goal of expanding indication from a general indication for the ablation of cardiac tissue to an indication from the FDA for the treatment of atrial fibrillation. Dr Ad discusses the AtriCure ICE-AFIB trial which will evaluate safety and effectiveness of the AtriCure CryoICE ablation system for treatment of long standing Persistent atrial fibrillation in open concomitant cardiac surgery.
The trials will look at similar endpoints that include freedom from atrial fibrillation. The goal for both trials is FDA approval if they meet all safety and efficacy endpoints. This will elevate the visibility for the field and more effectively treat patients.
↖ read less
read more ↘ of atrial fibrillation and the two trials the doctors are currently leading.
Dr. Lehr discusses the Medtronic Terminate AF Trial with the goal of expanding indication from a general indication for the ablation of cardiac tissue to an indication from the FDA for the treatment of atrial fibrillation. Dr Ad discusses the AtriCure ICE-AFIB trial which will evaluate safety and effectiveness of the AtriCure CryoICE ablation system for treatment of long standing Persistent atrial fibrillation in open concomitant cardiac surgery.
The trials will look at similar endpoints that include freedom from atrial fibrillation. The goal for both trials is FDA approval if they meet all safety and efficacy endpoints. This will elevate the visibility for the field and more effectively treat patients.
↖ read less
Comments 0
Login to view comments.
Click here to Login